预约演示
更新于：2025-08-19
Firsocostat
更新于：2025-08-19
概要
基本信息
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H31N3O8S |
InChIKeyZZWWXIBKLBMSCS-FQEVSTJZSA-N |
CAS号1434635-54-7 |
关联
7
项与 Firsocostat 相关的临床试验NCT03987074
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
ACTRN12619000655145
A Phase 1 Open-Label, Parallel-Group, Two-Treatment, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9674 and GS-0976 in Subjects with Normal Renal Function and Severe Renal Impairment
NCT03449446
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
100 项与 Firsocostat 相关的临床结果
登录后查看更多信息
100 项与 Firsocostat 相关的转化医学
登录后查看更多信息
100 项与 Firsocostat 相关的专利（医药）
登录后查看更多信息
197
项与 Firsocostat 相关的文献（医药）2025-07-01JOURNAL OF CLINICAL PHARMACOLOGY
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease
Article
作者: Nelson, Cara ; Watkins, Timothy R. ; Weber, Elijah J. ; Othman, Ahmed A. ; Younis, Islam R. ; Qin, Ann R.
Abstract:
Fenofibrate is contraindicated in patients with advanced hepatic fibrosis due to limited clinical data. We evaluated the pharmacokinetics and safety of fenofibrate in participants with mild hepatic impairment (phase 1 study) or advanced fibrosis due to metabolic‐associated fatty liver disease (MAFLD; phase 2a study). In the phase 1 study, participants with mild hepatic impairment and healthy matched controls (each n = 10) received a single, oral dose of fenofibrate 48 mg. In the phase 2a study, participants with hypertriglyceridemia and advanced fibrosis due to MAFLD were randomly assigned (1:1) fenofibrate 48 mg (n = 15) or fenofibrate 145 mg (n = 16) combined with firsocostat 20 mg, taken orally once daily for 24 weeks. Pharmacokinetics and safety were assessed in both studies. In the phase 1 study, the AUCinf of fenofibric acid was 25% higher in participants with mild hepatic impairment than in healthy matched participants. In the phase 2a study, the AUCss,0‐24 of fenofibric acid (fenofibrate 48 mg dose) in participants with F3 fibrosis and F4 cirrhosis was approximately 60% and 80%, respectively, higher than the AUCinf in healthy participants in the phase 1 study, and was 20% higher in participants with F4 cirrhosis than in participants with F3 fibrosis. In both studies, most adverse events and laboratory abnormalities were grade 1‐2. In the phase 2a study, three participants had grade 3 hypertriglyceridemia. Fenofibrate was well tolerated, and modest differences were observed in fenofibric acid exposure in participants with mild hepatic impairment or advanced fibrosis due to MAFLD.
2025-06-01Journal of the Chinese Medical Association
Far-infrared therapy on arteriovenous fistula among hemodialysis patients: A systematic review and meta-analysis
Review
作者: Azman, Mohd Yacob ; Che Yusof, Ruhana ; Norhayati, Mohd Noor
Background::
Far-infrared (FIR) is one of the alternative therapies used to improve the performance of arteriovenous fistula (AVF) in hemodialysis patients. This review was done to pool the mean difference of vascular access flow and AVF diameter between the FIR and the control group. It also pooled the risk ratio of 1-year unassisted AVF patency, AVF occlusion, surgical intervention, and AVF malfunction between groups.
Methods::
The studies were reviewed using a systematic review, meta-analysis, and a search of four databases. The risk of bias in non-randomized studies of interventions (ROBINS-I) and the Revised Cochrane risk-of-bias instrument for randomized trials (RoB-2) were used to assess the data quality. The meta-analysis was performed using the random-effects model by inverse variance to measure the mean difference for continuous data and the Mantel-Haenszel method for dichotomous data.
Results::
FIR therapy group had a significant difference in risk ratio in 1-year unassisted AVF patency (risk ratio: 1.23 [95% CI, 1.12-1.36]), AVF occlusion (risk ratio: 0.24 [95% CI, 0.08-0.68]), surgical intervention (risk ratio: 0.45 [95% CI, 0.23-0.86]), and AVF malfunction (risk ratio: 0.44 [95% CI, 0.30-0.62]) compared with the control group. However, for vascular access flow and AVF diameter, there was no difference between the groups (mean difference: 68.38 [95% CI, −3.84 to 140.61] and −0.07 [95% CI, −0.31 to 0.17], respectively).
Conclusion::
The findings showed that the FIR therapy improved AVF performance. However, the limited number of studies primarily from Taiwanese may act differently from others.
2025-06-01BRAIN RESEARCH BULLETIN
The effects and mechanisms of far-infrared ray on depression-like behavior induced by CRS in mice
Article
作者: Nie, Lijuan ; Liu, Wanbin ; Ling, Yian ; Li, Jing ; Zhu, Cuizhen ; Xia, Qingrong ; Gao, Yejun
PURPOSE:
Far-infrared ray (FIR) is an electromagnetic wave known to impart health benefits against various pathophysiological conditions, including diabetes mellitus, renocardiovascular disorders, stress, and depression, among others. However, the precise impact of FIR on major depressive disorder (MDD) and the underlying molecular mechanisms remain unclear. Here, we aimed to investigate the effects and elucidate the molecular mechanisms of FIR on depression-like behavior in mice.
METHODS:
A mouse model of depression was established using chronic restraint stress (CRS). Behavioral tests were performed to assess alterations in depression-like behaviors. Biochemical methods were employed to measure the levels of IL-1β, IL-6, TNF-α, S100β, IL-17, melatonin (MT), 5-hydroxytryptamine (5-HT), glutathione (GSH), malondialdehyde (MDA), brain-derived neurotrophic factor (BDNF), and corticosterone (CORT) in mice serum. Similarly, the levels of IL-1β, IL-6, TNF-α, S100β, IL-17, and MT in mice brains were measured using biochemical methods. Hematoxylin-eosin and Nissl staining were utilized to detect morphological changes in the mice hippocampus. In addition, the structure and mitochondrial morphology of hippocampal neurons and microglia were studied using transmission electron microscopy (TEM).
RESULTS:
The results of behavioral tests revealed that FIR mitigated the depression-like behaviors induced by CRS. FIR also reversed the levels of IL-1β, IL-6, TNF-α, and related cytokines in the periphery and brain. The results of hematoxylin-eosin and Nissl staining showed that FIR improved the damage of mice's hippocampus. Additionally, TEM revealed that FIR alleviated the damage of CRS to hippocampal neurons and microglia.
CONCLUSION:
Our findings suggest that FIR can ameliorate depression-like behavior induced by CRS in mice. FIR can reverse the levels of related cytokines in the periphery and brain, and alleviate damage to neurons and microglia, which may constitute its underlying molecular mechanism.
61
项与 Firsocostat 相关的新闻（医药）2025-08-18
财报并购疫苗临床3期抗体药物偶联物
2025-08-12
·药时空
财报ASH会议临床2期临床3期突破性疗法
2025-08-11
·医药速览
财报临床3期临床2期ASH会议
100 项与 Firsocostat 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代偿期肝硬化 | 临床2期 | 美国 | 2018-03-21 | |
| 代偿期肝硬化 | 临床2期 | 澳大利亚 | 2018-03-21 | |
| 代偿期肝硬化 | 临床2期 | 加拿大 | 2018-03-21 | |
| 代偿期肝硬化 | 临床2期 | 中国香港 | 2018-03-21 | |
| 代偿期肝硬化 | 临床2期 | 新西兰 | 2018-03-21 | |
| 代偿期肝硬化 | 临床2期 | 波多黎各 | 2018-03-21 | |
| 肝纤维化 | 临床2期 | 美国 | 2018-03-21 | |
| 肝纤维化 | 临床2期 | 澳大利亚 | 2018-03-21 | |
| 肝纤维化 | 临床2期 | 加拿大 | 2018-03-21 | |
| 肝纤维化 | 临床2期 | 中国香港 | 2018-03-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 108 | Semaglutide+Cilofexor tromethamine | 構襯遞餘製衊簾構築夢(範鹽淵窪醖夢醖襯壓積) = Treatments were well tolerated - the incidence of adverse events was similar across groups (73-90%) and most events were gastrointestinal in nature. 範淵構簾鬱襯廠壓夢製 (簾構蓋壓襯簾範顧艱鹽 ) 更多 | 积极 | 2022-04-16 | ||
临床2期 | 66 | 壓齋獵願積淵襯繭艱範(醖壓蓋觸鬱網醖壓網廠) = most treatment-emergent adverse events were Grade 1 to 2 severity 網淵簾膚膚繭廠網艱鹽 (獵遞構憲齋糧餘膚鏇齋 ) 更多 | 积极 | 2022-01-06 | |||
临床2期 | 109 | (Semaglutide) | 鏇積壓構蓋獵顧範網觸 = 衊窪範鹽繭網憲夢艱糧 廠壓艱簾夢憲衊夢築齋 (顧網衊範遞艱夢鹽艱淵, 鏇壓艱網蓋窪齋鬱窪顧 ~ 廠築選艱簾襯獵顧鹹膚) 更多 | - | 2021-07-15 | ||
(Semaglutide + Firsocostat 20 mg) | 鏇積壓構蓋獵顧範網觸 = 衊網網網醖鏇蓋鏇鑰艱 廠壓艱簾夢憲衊夢築齋 (顧網衊範遞艱夢鹽艱淵, 鹹網襯製鹹憲糧觸艱網 ~ 廠製鑰窪鹹獵廠襯簾膚) 更多 | ||||||
临床2期 | 395 | Placebo to match SEL | 餘衊積觸製齋製獵網鏇 = 遞範餘壓鏇獵憲鹹顧網 選艱襯膚衊壓鹽憲膚製 (餘壓醖鹽淵夢鹹網憲鹹, 憲範製鑰憲觸鹹齋簾鑰 ~ 醖夢鑰積夢鹽夢鹹衊積) 更多 | - | 2020-12-03 | ||
临床2期 | 127 | Placebo+Firsocostat (Firsocostat 5 mg) | 艱襯觸鏇窪顧襯繭選壓 = 顧積艱鏇齋繭遞鏇構醖 艱範艱獵餘鬱壓鏇選鑰 (鹹齋構觸製蓋艱糧齋憲, 顧膚淵顧襯餘憲衊膚遞 ~ 構鹽獵製餘淵獵夢壓齋) 更多 | - | 2020-07-24 | ||
Placebo+Firsocostat (Firsocostat 20 mg) | 艱襯觸鏇窪顧襯繭選壓 = 廠餘壓艱鏇觸鹽顧築衊 艱範艱獵餘鬱壓鏇選鑰 (鹹齋構觸製蓋艱糧齋憲, 遞壓壓遞夢鑰餘鹽艱醖 ~ 觸窪築網積製糧範鹹願) 更多 | ||||||
临床2期 | 126 | GS-0976 20 mg | 顧夢窪窪鑰築繭艱艱蓋(蓋構醖觸鏇鏇製廠膚蓋) = 顧襯鏇淵構選獵膚艱廠 積觸積窪襯鹽觸製廠壓 (獵繭構艱窪積製顧壓鑰 ) | - | 2018-11-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用